A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
University of Florida
Pfizer
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
National Institutes of Health Clinical Center (CC)